Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFQ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,688
Award facts
- Contract value 100% obligated
- $23,688.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $23,688.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The award, issued on January 20, 2026, with an ultimate completion date of February 10, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the contractor competed in unrestricted federal procurement. DMS Pharmaceutical Group is performing the work at its Park Ridge facility and will deliver the pharmaceutical product to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy. The parent contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the contractor to supply a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. The company's established performance across numerous delivery orders spanning oncology treatments, immunosuppressants, specialty pharmaceuticals, and routine medications demonstrates its capability to serve as a critical pharmaceutical supplier for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCFQ1?
SPE2DR26FCFQ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FCFQ1 worth?
The government has obligated $23,688 on SPE2DR26FCFQ1.
Is contract SPE2DR26FCFQ1 an order under another contract?
Yes. SPE2DR26FCFQ1 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFQ1 competed?
The extent of competition for SPE2DR26FCFQ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award